Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells

Michael Ramirez, Satwik Rajaram, Robert J. Steininger, Daria Osipchuk, Maike A. Roth, Leanna S. Morinishi, Louise Evans, Weiyue Ji, Chien Hsiang Hsu, Kevin Thurley, Shuguang Wei, Anwu Zhou, Prasad R. Koduru, Bruce A. Posner, Lani F. Wu, Steven J. Altschuler

Research output: Contribution to journalArticle

112 Citations (Scopus)

Abstract

Cancer therapy has traditionally focused on eliminating fast-growing populations of cells. Yet, an increasing body of evidence suggests that small subpopulations of cancer cells can evade strong selective drug pressure by entering a 'persister' state of negligible growth. This drug-tolerant state has been hypothesized to be part of an initial strategy towards eventual acquisition of bona fide drug-resistance mechanisms. However, the diversity of drug-resistance mechanisms that can expand from a persister bottleneck is unknown. Here we compare persister-derived, erlotinib-resistant colonies that arose from a single, EGFR-addicted lung cancer cell. We find, using a combination of large-scale drug screening and whole-exome sequencing, that our erlotinib-resistant colonies acquired diverse resistance mechanisms, including the most commonly observed clinical resistance mechanisms. Thus, the drug-tolerant persister state does not limit-and may even provide a latent reservoir of cells for-the emergence of heterogeneous drug-resistance mechanisms.

Original languageEnglish (US)
Article number10690
JournalNature Communications
Volume7
DOIs
StatePublished - Feb 19 2016

Fingerprint

Drug Resistance
drugs
cancer
cells
Pharmaceutical Preparations
Neoplasms
Exome
Cells
Preclinical Drug Evaluations
Lung Neoplasms
sequencing
Pressure
lungs
Growth
therapy
acquisition
Screening
Population
screening
Erlotinib Hydrochloride

ASJC Scopus subject areas

  • Biochemistry, Genetics and Molecular Biology(all)
  • Chemistry(all)
  • Physics and Astronomy(all)

Cite this

Ramirez, M., Rajaram, S., Steininger, R. J., Osipchuk, D., Roth, M. A., Morinishi, L. S., ... Altschuler, S. J. (2016). Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. Nature Communications, 7, [10690]. https://doi.org/10.1038/ncomms10690

Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. / Ramirez, Michael; Rajaram, Satwik; Steininger, Robert J.; Osipchuk, Daria; Roth, Maike A.; Morinishi, Leanna S.; Evans, Louise; Ji, Weiyue; Hsu, Chien Hsiang; Thurley, Kevin; Wei, Shuguang; Zhou, Anwu; Koduru, Prasad R.; Posner, Bruce A.; Wu, Lani F.; Altschuler, Steven J.

In: Nature Communications, Vol. 7, 10690, 19.02.2016.

Research output: Contribution to journalArticle

Ramirez, M, Rajaram, S, Steininger, RJ, Osipchuk, D, Roth, MA, Morinishi, LS, Evans, L, Ji, W, Hsu, CH, Thurley, K, Wei, S, Zhou, A, Koduru, PR, Posner, BA, Wu, LF & Altschuler, SJ 2016, 'Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells', Nature Communications, vol. 7, 10690. https://doi.org/10.1038/ncomms10690
Ramirez, Michael ; Rajaram, Satwik ; Steininger, Robert J. ; Osipchuk, Daria ; Roth, Maike A. ; Morinishi, Leanna S. ; Evans, Louise ; Ji, Weiyue ; Hsu, Chien Hsiang ; Thurley, Kevin ; Wei, Shuguang ; Zhou, Anwu ; Koduru, Prasad R. ; Posner, Bruce A. ; Wu, Lani F. ; Altschuler, Steven J. / Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells. In: Nature Communications. 2016 ; Vol. 7.
@article{190dfa7785de4a8d9ee423785c3f84ce,
title = "Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells",
abstract = "Cancer therapy has traditionally focused on eliminating fast-growing populations of cells. Yet, an increasing body of evidence suggests that small subpopulations of cancer cells can evade strong selective drug pressure by entering a 'persister' state of negligible growth. This drug-tolerant state has been hypothesized to be part of an initial strategy towards eventual acquisition of bona fide drug-resistance mechanisms. However, the diversity of drug-resistance mechanisms that can expand from a persister bottleneck is unknown. Here we compare persister-derived, erlotinib-resistant colonies that arose from a single, EGFR-addicted lung cancer cell. We find, using a combination of large-scale drug screening and whole-exome sequencing, that our erlotinib-resistant colonies acquired diverse resistance mechanisms, including the most commonly observed clinical resistance mechanisms. Thus, the drug-tolerant persister state does not limit-and may even provide a latent reservoir of cells for-the emergence of heterogeneous drug-resistance mechanisms.",
author = "Michael Ramirez and Satwik Rajaram and Steininger, {Robert J.} and Daria Osipchuk and Roth, {Maike A.} and Morinishi, {Leanna S.} and Louise Evans and Weiyue Ji and Hsu, {Chien Hsiang} and Kevin Thurley and Shuguang Wei and Anwu Zhou and Koduru, {Prasad R.} and Posner, {Bruce A.} and Wu, {Lani F.} and Altschuler, {Steven J.}",
year = "2016",
month = "2",
day = "19",
doi = "10.1038/ncomms10690",
language = "English (US)",
volume = "7",
journal = "Nature Communications",
issn = "2041-1723",
publisher = "Nature Publishing Group",

}

TY - JOUR

T1 - Diverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells

AU - Ramirez, Michael

AU - Rajaram, Satwik

AU - Steininger, Robert J.

AU - Osipchuk, Daria

AU - Roth, Maike A.

AU - Morinishi, Leanna S.

AU - Evans, Louise

AU - Ji, Weiyue

AU - Hsu, Chien Hsiang

AU - Thurley, Kevin

AU - Wei, Shuguang

AU - Zhou, Anwu

AU - Koduru, Prasad R.

AU - Posner, Bruce A.

AU - Wu, Lani F.

AU - Altschuler, Steven J.

PY - 2016/2/19

Y1 - 2016/2/19

N2 - Cancer therapy has traditionally focused on eliminating fast-growing populations of cells. Yet, an increasing body of evidence suggests that small subpopulations of cancer cells can evade strong selective drug pressure by entering a 'persister' state of negligible growth. This drug-tolerant state has been hypothesized to be part of an initial strategy towards eventual acquisition of bona fide drug-resistance mechanisms. However, the diversity of drug-resistance mechanisms that can expand from a persister bottleneck is unknown. Here we compare persister-derived, erlotinib-resistant colonies that arose from a single, EGFR-addicted lung cancer cell. We find, using a combination of large-scale drug screening and whole-exome sequencing, that our erlotinib-resistant colonies acquired diverse resistance mechanisms, including the most commonly observed clinical resistance mechanisms. Thus, the drug-tolerant persister state does not limit-and may even provide a latent reservoir of cells for-the emergence of heterogeneous drug-resistance mechanisms.

AB - Cancer therapy has traditionally focused on eliminating fast-growing populations of cells. Yet, an increasing body of evidence suggests that small subpopulations of cancer cells can evade strong selective drug pressure by entering a 'persister' state of negligible growth. This drug-tolerant state has been hypothesized to be part of an initial strategy towards eventual acquisition of bona fide drug-resistance mechanisms. However, the diversity of drug-resistance mechanisms that can expand from a persister bottleneck is unknown. Here we compare persister-derived, erlotinib-resistant colonies that arose from a single, EGFR-addicted lung cancer cell. We find, using a combination of large-scale drug screening and whole-exome sequencing, that our erlotinib-resistant colonies acquired diverse resistance mechanisms, including the most commonly observed clinical resistance mechanisms. Thus, the drug-tolerant persister state does not limit-and may even provide a latent reservoir of cells for-the emergence of heterogeneous drug-resistance mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=84958999430&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84958999430&partnerID=8YFLogxK

U2 - 10.1038/ncomms10690

DO - 10.1038/ncomms10690

M3 - Article

C2 - 26891683

AN - SCOPUS:84958999430

VL - 7

JO - Nature Communications

JF - Nature Communications

SN - 2041-1723

M1 - 10690

ER -